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Human respiratory syncytial virus (RSV) inhibits type I interferon-induced gene expression by decreasing expression of signal transducer and
activator of transcription (Stat)2. To identify the RSV protein that mediates effects on Stat2, airway epithelial cells were infected with vaccinia
virus vectors that express single RSV proteins. Expression of RSV nonstructural (NS)2 protein alone was sufficient to decrease Stat2 levels.
Furthermore, decreasing RSV NS2 levels using RNA interference in respiratory epithelial cells inhibited the RSV-mediated decrease in Stat2
expression. Airway epithelial cells were also infected with equivalent inoculums of RSV without or with single gene deletions of NS1 or NS2.
RSV infection without NS2 expression did not result in decreased Stat2 levels or loss of type I interferon-dependent signaling, indicating that NS2
expression is necessary for RSVeffects on Stat2. Taken together, our results indicate that NS2 regulates Stat2 levels during RSV infection, thereby
modulating viral effects on interferon-dependent gene expression.
D 2005 Elsevier Inc. All rights reserved.Keywords: Airway epithelial cell; JAK-STAT pathway; RNA interferenceIntroduction
Human respiratory syncytial virus (RSV) has generated
intense research interest since its identification over 40 years
ago because it infects virtually 100% of children within the
first few years of life, is the most frequent cause of lower
respiratory tract infection (pneumonia and bronchiolitis) in
infants and young children, and has important roles in
exacerbation of several respiratory diseases (Sigurs, 2001).
RSV is an enveloped, nonsegmented, single-stranded, negative
sense RNA virus in the subfamily Pneumovirinae of the
family Paramyxoviridae (Collins et al., 2001). The RSV
genome encodes 11 proteins, and shares several genes with
other paramyxoviruses that include nucleocapsid proteins (N,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.09.009
* Corresponding author. Fax: +1 319 353 6406.
E-mail address: dwight-look@uiowa.edu (D.C. Look).P, and L), surface proteins (F and G), and a matrix protein
(M). Other viral proteins that RSV shares with para-
myxoviruses have less well-defined functions and include
SH and M2-1. Proteins in RSV that are not clearly
homologous with other paramyxoviruses include M2-2, and
the nonstructural proteins NS1 and NS2. RSV gains entry into
host cell by cell-surface fusion, replicates in the cytoplasm,
and acquires a lipid envelope from the host cell plasma
membrane by budding. Epithelial cells are the primary site of
viral replication in the airway, with RSV entry and exit
primarily through the apical surface (Zhang et al., 2002).
A central feature of the host response to viral infection in
the airway is activation of cellular genes that are important in
innate and adaptive immunity by a potent group of mediators
termed interferons (Decker et al., 2002). RSV is a potent
inducer of type I interferon release from infected airway
epithelial cells (Garofalo et al., 1996; Jamaluddin et al., 2001;
Ramaswamy et al., 2004). Type I interferons (IFN-a and IFN-6) 328 – 339
www.e
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complex linked to a Janus family kinase-signal transducer and
activator of transcription (JAK-STAT) signaling cascade
(Taniguchi and Takaoka, 2001). Activation of the type I
interferon-driven pathway is triggered by engagement and
multimerization of the IFN-a-receptor (IFNAR) by IFN-a or
IFN-h, phosphorylation of IFNAR1-associated Tyk2 and
IFNAR2-associated Jak1 tyrosine kinases, and then phosphor-
ylation of IFNAR1 and IFNAR2 (Darnell et al., 1994;
Platanias et al., 1994). Phosphorylation of the IFNAR1 chain
of the IFN-a receptor results in recruitment, phosphorylation,
and subsequent release of Stat2 and Stat1 from the receptor
(Leung et al., 1995; Qureshi et al., 1996). Activated Stat2 and
Stat1 associate with interferon regulatory factor (IRF)-9 to
form the transcriptional activator complex interferon-stimulat-
ed gene factor 3 (ISGF3), which translocates to the nucleus
and binds specific DNA recognition sequences to activate
transcription of type I interferon-inducible genes (Horvath et
al., 1996). Many genes are induced by type I interferon, but
several, including MxA, 2V,5V-oligoadenylate synthase (2,5-
OAS), and protein kinase R (PKR), are more specific to type I
interferon and have antiviral properties that are particularly
important for establishment of a host cell antiviral state (Katze
et al., 2002).
The success of RSV in establishing productive infections
in human airway epithelia depends on viral expression of
mechanisms for evasion of innate and acquired immune
responses. A common theme for paramyxoviral subversion of
interferon-dependent antiviral effects is through inhibition of
interferon signal transduction. Although paramyxoviruses are
genotypically related, these viruses have evolved a variety of
different strategies to counteract the antiviral effects of
interferons (Gotoh et al., 2001; Young et al., 2000). We have
reported previously that RSV selectively inhibits the type I
interferon JAK-STAT signaling pathway in airway epithelial
cells resulting in reduced and delayed antiviral gene
expression, but has little effect on type II interferon (IFN-
g)-induced signaling or gene expression (Ramaswamy et al.,
2004). RSV effects on type I interferon signaling is mediated
through degradation of Stat2 that is likely proteasome-
dependent. RSV lacks the C and V accessory proteins that
mediate interferon resistance in many paramyxoviruses and
the proteins produced by human RSV that modulate
interferon signaling are being defined (Lo et al., 2005; Spann
et al., 2004, 2005).
In this report, we demonstrate that expression of the RSV
NS2 protein is necessary and sufficient for inhibition of type I
interferon-dependent signaling. Expression of NS2 resulted in
decreased airway epithelial cell Stat2 expression with conse-
quent blockade of type I interferon-dependent gene expres-
sion. Furthermore, decreased NS2 levels in RSV-infected cells
using RNA interference or viral mutation inhibited RSV
effects on Stat2. Our results support the concept that specific
RSV proteins modulate immune response gene expression in
airway epithelial cells, which may allow for evasion of the
airway defense response and establishment of a productive
infection.Results
RSV NS2 expression is sufficient to decrease epithelial cells
Stat2 levels
To begin identification of RSV proteins that modulate
Stat2 levels in human airway epithelial cells, 9 of the 11
RSV proteins were individually expressed in human tra-
cheobronchial epithelial (hTBE) cells using recombinant
vaccinia viruses under conditions in which the majority of
the cells in the sample were infected. Expression of RSV M
and P protein had a slight effect on Stat2 expression, but
RSV NS2 expression markedly decreased Stat2 levels as
detected using immunoblot analysis of epithelial cells
infected with vector for 24 h (Fig. 1A). Control vaccinia
vector or expression of the other RSV proteins had little
effect on Stat2 under these conditions. The possibility that
decreased Stat2 levels were due to NS2-induced epithelial
cell cytotoxicity was excluded by assessing epithelial cell
uptake of ethidium homodimers, and these results indicated
no significant cytotoxic effects of NS2 expression (Fig. 1B).
Similar to wild-type RSV infection (Ramaswamy et al.,
2004), Stat2 levels were not altered after expression of NS2
in hTBE cells that were pretreated with the cell-permeable
nonspecific proteasome inhibitor MG-132 (Fig. 1C). These
results suggest that RSV NS2 is sufficient to decrease Stat2
levels in airway epithelial cells, and through this effect
modulates type I interferon signaling and gene expression.
Therefore, subsequent experiments were directed at deter-
mining whether NS2 is required to decrease epithelial cell
Stat2 levels during RSV infection.
RNA interference of NS2 expression modulates RSV effects on
Stat2 levels
To manipulate RSV protein levels, we initially tested
RNA interference strategies that require transfection of
sequence-specific 21 or 25–27 nucleotide double-stranded
RNA molecules into A549 respiratory epithelial cells (Bitko
and Barik, 2001; Kim et al., 2004). Experiments using
vaccinia virus vectors to express RSV NS1 and NS2
indicated that a 21 nucleotide double-stranded small inter-
fering (si)RNA significantly decreased NS2, but not NS1,
mRNA levels (Fig. 2A). In contrast, multiple RNA interfer-
ence strategies to decrease NS1 were tested, but for unclear
reasons, all affected NS2 levels in addition to inhibiting NS1
expression. A 25–27 nucleotide double-stranded siRNA
against NS1 gave the best specificity, as some NS2 protein
was detectable after infection of epithelial cells with vaccinia
virus expressing NS2 (Fig. 2B). The effect of NS2 expressed
by vaccinia virus on Stat2 levels in A549 cells was inhibited
using siRNA directed against NS2, but not NS1 or control
siRNA (Fig. 2C). These preliminary results support the
possibility that decreased Stat2 levels after RSV infection are
mediated by NS2 expression.
RNA interference was then tested on viral protein
expression after wild-type RSV infection. We found that
M. Ramaswamy et al. / Virology 344 (2006) 328–339330with potent and specific silencing of NS2 expression using
the 21 nucleotide siRNA, RSV lost the capacity to inhibit
Stat2 expression in epithelial cells (Fig. 3A). The reported
lack of requirement for NS2 in expression of other viral
proteins was confirmed when we observed that inhibition of
expression of this viral protein had little effect on expression
of RSV P (Fig. 3A) and other viral proteins (results not
shown) after infection. Experiments using siRNA against
NS1 were less informative because siRNA tested were less
potent and specific, despite the use of two different strategies
(Figs. 3B and C). Both RNA interference strategies against
NS1 caused a decrease in NS2 expression that was similar,
but more complete after RSV infection compared to vaccinia
vector expression of RSV proteins. As expected, we
observed that siRNA directed at the P gene resulted in a
global decrease in RSV protein expression including NS2.
Under all conditions, restoration of Stat2 levels in RSV-infected cells correlated with loss of NS2 expression. Taken
together, our RNA interference experiments were consistent
with the possibility that NS2 is necessary for RSV-induced
Stat2 degradation, but did not completely exclude a role for
other viral genes.
RSV is a potent inducer of IFN-h release from
respiratory epithelial cells, although RSV effects on type I
interferon signaling are identical in epithelial cells exposed
to IFN-a or IFN-h (Jamaluddin et al., 2001; Ramaswamy et
al., 2004; Spann et al., 2004). However, RNA interference
may also activate type I interferon production and antiviral
gene expression in some systems, and thus could potentially
attenuate viral replication and RSV-induced decreases in
Stat2 levels (Sledz et al., 2003). We were reassured that our
RNA interference systems had minimal confounding effects
by the observation that control siRNA did not cause a
global decrease in viral gene expression (Fig. 3). In
addition, transfection of siRNA molecules into A549 cells
did not cause detectable IFN-h release, nor significantly
affect virus-induced IFN-h release in RSV-infected cells
(Fig. 4A). Because RSV is a relatively poor inducer of IFN-
a release from airway epithelial cells, we thought it was
unlikely that other type I interferon release is activated by
our RNA interference systems (Ramaswamy et al., 2004;
Spann et al., 2004). However, to support this conclusion,
interferon signaling pathway activation and gene expression
were also assessed. Type I and type II interferon-driven
transcription of antiviral genes in airway epithelial cells
requires tyrosine phosphorylation of Stat1 that is mediated
through specific JAK-STAT pathways (Darnell et al., 1994).
In experiments using immunoblot analysis with phosphory-
lation-specific Stat1 antibodies to detect activation of this
transcription factor, siRNA did not induce Stat1 activation
30 min or 24 h after transfection (Fig. 4B). This finding
correlated with a lack of detectable increase in expression of
the type I interferon-inducible genes MxA or PKR in
epithelial cells exposed to siRNA.Fig. 1. RSV NS2 expression is sufficient to decrease Stat2 levels. (A) Stat2,
RSV proteins (using polyclonal antiserum that recognizes multiple viral
proteins), RSV NS1 and NS2 (using polyclonal antiserum that reacts more
strongly with NS1 compared to NS2), and h-actin (to verify equivalent protein
isolation and loading) protein levels in hTBE cells were assessed using
immunoblot analysis. Extracts for analysis were from cell monolayers that were
left uninfected or were infected at MOI 10 for 24 h with vaccinia virus vectors
that express control or individual RSV proteins. The positions of Stat2, NS1,
NS2, and h-actin are indicated by arrows, and detection of NS1 and NS2
required two different exposures of the immunoblot membrane. (B) Dead and
live hTBE cell numbers were quantified by detection of plasma membrane
permeability to ethidium homodimers in dead cells and intracellular esterase
activity in live cells. Cells were left uninfected or infected with vaccinia virus
vectors at MOI 10 for 24 h. Values were calculated as live cells/total cells, each
condition represents the mean T SD for 3 microscopic fields (90–200 cells/
field), and a statistically significant difference between levels in any condition
was not detected. (C) Stat2, and RSV NS1 and NS2 protein levels in hTBE
cells were assessed using immunoblot analysis of extracts from cell monolayers
that were pretreated with control DMSO or 2.1 AMMG-132, and then were left
uninfected or were infected at MOI 10 for 24 h with vaccinia virus vectors that
express control or individual RSV proteins. Ponceau S staining of the
membrane was used to verify equivalent protein isolation and loading.
Fig. 2. RNA interference of NS2 expression modulates NS2 effects on Stat2
levels. (A) RSV NS1 and NS2 mRNA levels in A549 respiratory epithelial cells
were determined using real-time RT-PCR analysis of samples from cell
monolayers that were initially left untreated or were transfected for 4 h with
control siRNA or siRNA against NS1 (using a 21 nucleotide siRNA design)
(Bitko and Barik, 2001) or NS2 (using a 25–27 nucleotide siRNA design)
(Kim et al., 2004). Cell monolayers were then infected at MOI 10 for 24 h with
vaccinia virus vectors that express RSV NS1 (solid bars) or NS2 (open bars).
NS1 levels in cell samples infected with vector that expresses NS1, and NS2
levels in cell samples infected with vector that expresses NS2 are presented,
and NS1 and NS2 mRNAwas not detected in samples infected with vectors that
express the opposite RSV protein. Values are expressed as mean mRNA level
compared to control hypoxanthine phosphoribosyltransferase (HPRT) mRNA
level T SD for duplicate samples, and a significant difference in mRNA levels
compared to cells treated with the corresponding control siRNA is indicated by
an asterisk. (B) NS2, NS1, and h-actin protein levels in A549 cells were
assessed using immunoblot analysis of extracts from cell monolayers that were
initially transfected with siRNA against NS1 or NS2 as in panel A. Cell
monolayers were then left uninfected or infected at MOI 10 for 24 h with
vaccinia virus vectors that express RSV NS1 or NS2. (C) Stat2 and h-actin
protein levels in A549 cells were assessed using immunoblot analysis of
extracts from cell monolayers that were initially left untreated or were
transfected with control siRNA or siRNA against NS1 or NS2 as in panel A.
Cell monolayers were then left uninfected or infected at MOI 10 for 24 h with
vaccinia virus vectors that express RSV NS1 or NS2.
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signaling
Based on the lack of definitive evidence in our RNA
interference experiments that excluded a role for viral
proteins other than NS2 in RSV modulation of Stat2 levels,RSV with deletion of the NS2 or NS1 genes were also tested
for effects on Stat2 expression (Jin et al., 2000). For these
experiments, hTBE cells were infected under conditions that
resulted in infection of the majority of cells in the samples as
verified by immunofluorescence staining for viral protein
expression. Effects of NS gene deletion on viral gene mRNA
levels were assessed using real-time RT-PCR analysis, and
the results confirmed selective loss of NS1 or NS2 mRNA
expression (Fig. 5A). Furthermore, there were decreased
RSV M gene (Fig. 5A) and P gene (Fig. 5B, and results not
shown) expression in cells infected with NS1- or NS2-
deficient RSV compared to wild-type virus. These results
correlate with a previous report indicating restricted replica-
tion of RSV deficient in either NS gene in respiratory
epithelial cells (Spann et al., 2004). However, a key finding
was that infection with either wild-type RSV or RSV
deficient in NS1 expression resulted in decreased epithelial
cell levels of Stat2 (Fig. 5B). In contrast, RSV without NS2
expression lost the capacity to alter Stat2 levels. Moreover,
RSV that expressed NS2 inhibited Stat1 phosphorylation in
response to IFN-a, while RSV deficient in NS2 lost this
capacity (Fig. 5C). The results correlate with our results
using RNA interference and indicate that NS2 expression is
necessary for RSV inhibition of Stat2 expression and Stat1
activation in airway epithelial cells.
RSV that express NS2 specifically affect Stat2 expression and
antiviral gene expression
Modulation of Stat2 levels is an important mechanism for
inhibition of type I interferon signaling in airway epithelial
cell infected with RSV, resulting in intact upstream signaling
events, but loss of Stat2-dependent functions (Ramaswamy et
al., 2004). Based on our findings concerning RSV NS2 effects
on Stat2 levels, we performed additional experiments directed
at assessment of mutant virus effects on upstream and
downstream components in the signaling cascade. We
confirmed that wild-type and NS1-deficient RSV were similar
in their ability to inhibit IFN-a-induced Stat2 expression and
phosphorylation after as little as 6–12 h of infection, and this
effect correlated with expression of NS2 (Fig. 6A). In contrast,
NS2-deficient RSV had little effect on IFN-a-dependent
phosphorylation of Stat2. Immunofluorescence staining for
viral proteins indicated that the multiplicity of infection (MOI)
of 15 based on plaque titration assay using Vero cells and
used for these experiments resulted in infection of 88–93 T
2% of hTBE cells by wild-type and mutant RSV. Thus,
incomplete loss of Stat2 expression and antiviral gene
induction in many of our experiments likely reflects incom-
plete infection of all cells, as well as the relatively early time
points after inoculation that were examined. Epithelial
signaling events upstream of Stat2 appeared to be maintained
with all RSV mutants tested because infection of hTBE cells
with wild-type, NS1-deficient, or NS2-deficient RSV had little
effects on IFN-a-induced phosphorylation of Tyk2 (Fig. 6B).
Similarly, no effects of wild-type or mutant RSV on type II
interferon (IFN-g) activation of Stat1 were demonstrated,
Fig. 3. RNA interference of NS2 expression modulates RSVeffects on Stat2 levels. (A) Stat2, and RSV NS2, NS1, and P protein levels in A549 respiratory epithelial
cells were assessed using immunoblot analysis of extracts from cell monolayers that were initially left untreated or were transfected with control siRNA or siRNA
against NS2 (using a 21 nucleotide siRNA design) (Bitko and Barik, 2001), and then were left uninfected or were infected with RSV at MOI 15 for 24 h. (B) Stat2,
and RSV NS2, NS1, and P protein levels in A549 cells were assessed using immunoblot analysis of extracts from cell monolayers that were initially left untreated or
were transfected with control siRNA or siRNA against NS1 (using a 25–27 nucleotide siRNA design) (Kim et al., 2004), and then were left uninfected or were
infected with RSV at MOI 15 for 24 h. (C) Stat2, and RSV NS2, NS1, and P protein levels in A549 cells were assessed using immunoblot analysis of extracts from
cell monolayers that were initially left untreated or were transfected with siRNA against NS1 or P (using a similar 21 nucleotide siRNA design as in panel A) (Bitko
and Barik, 2001), and then were left uninfected or were infected with RSVat MOI 15 for 24 h. In panels A–C, staining of proteins on the membrane with Ponceau S
dye was used to verify equivalency of protein isolation and loading.
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interferon signaling (Fig. 6C).
To assess viral effects on interferon-dependent gene
expression, we tested viral effects on Vero cells that do
not release IFN-a or h, thereby allowing exogenous
administration of type I interferons with precise control over
the timing and levels of interferon exposure during experi-
ments. Both wild-type and NS1-deficient RSV significantly
inhibited IFN-a-induction of MxA expression in Vero cells,
while NS2-deficient RSV had much less effect (Fig. 7A). We
were unable to confirm effects on MxA protein levels in
Vero cells using immunoblot analysis, which is likely due to
the relatively low level of expression in these cells, even
with interferon treatment. However, wild-type and NS1-
deficient RSV inhibited IFN-a-induction of PKR proteinFig. 4. RNA interference effects on the epithelial cell type I interferon system. (
immunoassay with cell monolayers that were initially left untreated or were trans
uninfected or were infected with RSVat MOI 15 for 24 h. Values are expressed as m
and total Stat1 protein levels in A549 cells were assessed using immunoblot analys
with 100 nM control siRNA or siRNA against NS1 or NS2 followed by incubatio
samples were incubated with 1000 units/ml of IFN-a for the same durations to alloexpression in Vero cells, while infection with NS2-deficient
RSV had minimal effects on PKR levels after IFN-a
treatment compared to uninfected control (Fig. 7B). These
results correlate RSV NS2 regulation of type I interferon-
dependent signaling with antiviral gene expression. The
effects of mutant viruses on antiviral gene expression were
also tested in hTBE cells using quantitative real-time RT-
PCR analysis. Unlike Vero cells, human respiratory epithelial
cells are competent for type I interferon release, with
increased levels starting to appear after 12–14 h of infection
(Ramaswamy et al., 2004; Spann et al., 2004; and results not
shown). MxA mRNA expression was induced after wild-type
RSV infection of hTBE cells, and this effect was markedly
decreased in cells infected with NS1-deficient RSV (Fig.
7C). In contrast, NS2-deficient RSV infection induced thisA) IFN-h release from hTBE cells was determined using an enzyme-linked
fected with the indicated concentration of control siRNA, and then were left
ean T SD (n = 3), and ND = none detected. (B) MxA, PKR, and phosphorylated
is of extracts from cell monolayers that were left untreated or were transfected
n in media for 0.5 or 24 h. To assure cell response to type I interferon, some
w for comparison.
Fig. 5. NS2 expression is necessary for RSV to inhibit type I interferon
signaling. (A) RSV NS1 (closed bar), NS2 (open bar), and M (gray bar) gene
mRNA levels in hTBE cells were determined using real-time RT-PCR analysis
of samples from cell monolayers that were left uninfected or were infected at
MOI 15 for 24 h with wild-type RSVor RSV deficient in NS1 or NS2. Values are
expressed as mRNA level compared to control HPRT mRNA level. (B) Stat2,
RSV P, and h-actin protein levels in hTBE cells were assessed using
immunoblot analysis of extracts from cell monolayers that were left uninfected
or were infected at MOI 15 for 24 h with wild-type RSVor RSV deficient in NS1
or NS2. (C) Phosphorylated and total Stat1, RSV P, and h-actin protein levels in
hTBE cells were assessed using immunoblot analysis of extracts from cell
monolayers that were left uninfected or were infected at MOI 15 for 12 h with
wild-type RSVor RSV deficient in NS1 or NS2, followed by incubation without
or with 1000 units/ml of IFN-a for 30 min.
Fig. 6. RSV that express NS2 specifically affect Stat2 expression. (A)
Phosphorylated and total Stat2, RSV NS2, NS1, and P, and h-actin protein
levels in hTBE cells were assessed using immunoblot analysis of extracts from
cell monolayers that were left uninfected or were infected at MOI 15 for the
indicated duration with wild-type RSV or RSV deficient in NS1 or NS2,
followed by incubation without or with 1000 units/ml of IFN-a for 15 min. (B)
Phosphorylated and total Tyk2 protein levels in hTBE cells were assessed using
immunoblot analysis of extracts from cell monolayers that were left uninfected
or were infected at MOI 15 for 24 h with wild-type RSV or RSV deficient in
NS1 or NS2, followed by incubation without or with IFN-a for 15 min. (C)
Phosphorylated and total Stat1 protein levels in hTBE cells were assessed using
immunoblot analysis of extracts from cell monolayers that were left uninfected
or were infected at MOI 15 for 18 h with wild-type RSV or RSV deficient in
NS1 or NS2, followed by incubation without or with 1000 units/ml of IFN-a or
100 units/ml of IFN-g for 30 min.
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MxA expression in response to RSV infection with NS gene
silencing using RNA interference was assessed in A549
cells. Epithelial cell infection with wild-type RSV combined
with siRNA against NS2 resulted in a significant increase in
MxA mRNA expression compared to RSV without gene
silencing. These results indicate that RSV uses NS2
expression to inhibit type I interferon-dependent signaling
and antiviral gene expression. Although other effects of NS
genes cannot be excluded, RSV effects on type I interferon
production and signaling appear to allow viral subversion of
interferon-dependent antiviral effects.Discussion
It has been proposed that a prerequisite for successful viral
invasion and replication in host cells is a mechanism for
avoiding effects of interferons (Barnard and McMillan, 1999;
Sen, 2001). For RSV, the observation that type I interferon
inefficiently inhibits viral replication in human epithelial cells
fits this paradigm (Atreya and Kulkarni, 1999; Gotoh et al.,
2001; Loveys et al., 2000; Young et al., 2000). Based on our
experiments, we conclude that RSV uses the NS2 protein to
subvert the antiviral effects of type I interferon after its release.
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RSV proteins suggested that NS2 protein expression is
sufficient for inhibition of epithelial cell Stat2 expression.
Subsequent studies in which specific viral protein expressionwas decreased or lost using RNA interference systems or
recombinant RSV with single gene deletions demonstrated a
requirement for the NS2 protein in inhibition of Stat2
expression. Thus, RSV NS2 protein is both sufficient and
necessary for inhibition of Stat2 expression, thereby decreasing
type I interferon-dependant signaling and gene expression.
Viruses use several targeted strategies to modify antiviral
effects of interferons classified broadly into: (1) minimizing
interferon production; (2) blocking interferon receptors; (3)
inhibiting interferon signaling; and (4) bypassing antiviral
protein effects (Ploegh, 1998; Sen, 2001). Use of viral
‘‘accessory’’ proteins to mediate interferon resistance has been
well described in the Paramyxoviridae family of viruses to
which RSV belongs. However, although paramyxoviruses are
genotypically related, these viruses have evolved a variety of
different strategies to counteract the antiviral effects of
interferons (Andrejeva et al., 2002; Gotoh et al., 2001; Young
et al., 2000). For example, human parainfluenza virus type 2
inhibits type I interferon signaling by decreasing host cell
levels of Stat2 (as has been shown for RSV), while mumps
virus and simian virus 5 inhibit type I and II interferon
signaling by decreasing levels of Stat1 (Kubota et al., 2001;
Parisien et al., 2001; Ulane and Horvath, 2002; Young et al.,
2000). Sendai virus inhibits both type I and II interferon
signaling through blockade of interferon-dependent tyrosine
phosphorylation of Stat1 and Stat2 and production of a protein
that binds Stat1 (Gotoh et al., 2003). The newly recognized
Nipah virus produces a protein that binds and inhibits
activation of Stat1 and Stat2 (Rodriquez et al., 2002). Thus,
a common theme for paramyxoviral subversion of interferon-
dependent antiviral effects is through inhibition of signal
transduction by viral protein interaction with STAT molecules.
RSV is similar to many viruses in its ability to modulate
interferon-dependent immune defense through multiple
mechanisms. Our finding that RSV inhibits Stat2 expressionFig. 7. NS2 deletion alters antiviral gene expression in airway epithelial cells
(A) MxA mRNA levels in Vero cells were determined using real-time RT
PCR analysis of samples from cell monolayers that were left uninfected o
were infected at MOI 15 for 6 h with wild-type RSV or RSV deficient in NS1
or NS2, followed by incubation without or with 1000 units/ml of IFN-a fo
12 h. (B) PKR, RSV P, and h-actin protein levels in Vero cells were assessed
using immunoblot analysis of extracts from cell monolayers that were lef
uninfected or were infected at MOI 15 for 6 h with wild-type RSV or RSV
deficient in NS1 or NS2, followed by incubation without or with 1000 units
ml of IFN-a for 12 h. (C) MxA mRNA levels in hTBE cells were determined
using real-time RT-PCR analysis of samples from cell monolayers that were
left uninfected or were infected at MOI 15 for 24 h with wild-type RSV o
RSV deficient in NS1 or NS2. (D) MxA mRNA levels in A549 cells were
determined using real-time RT-PCR analysis of samples from cell monolayers
that were initially left untreated or were transfected with control siRNA, o
siRNA against NS1 (using a 25–27 nucleotide siRNA design) (Kim et al.
2004) or NS2 (using a 21 nucleotide siRNA design) (Bitko and Barik, 2001)
and then were left uninfected or were infected with wild-type RSV at MOI 15
for 18 h. In panels A, C, and D, values are expressed as mean mRNA leve
compared to control HPRT mRNA level T SD (n = 2–3), and a significan
difference in mRNA levels compared to cells left uninfected but interferon
treated in panel A, cells infected with wild-type RSV in panel C, and cells
treated with control siRNA and infected with RSV in panel D is indicated by
an asterisk..
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other research groups (Lo et al., 2005). RSV also uses the NS1
and NS2 proteins to suppress the induction of type I and II
interferons (Spann et al., 2004, 2005). Viral effects on
interferon release are likely important because interferons have
important effects on nearby uninfected cells, although RSV
effects on type I interferon signaling likely decrease antiviral
effects in infected cells. However, other reports suggest that
human RSV has minimal effects on the function of interferon-
dependent JAK-STAT pathways. Atreya and Kulkarni reported
that A549 respiratory epithelial cells infected with RSV strain
A2 maintained interferon-mediated MxA expression and
inhibition of human parainfluenza virus type 3 replication
when epithelial cells were treated with type I interferon prior to
infection (Atreya and Kulkarni, 1999). Based on our results,
interferon pretreatment of epithelial cells in their experiments
would not allow time for expression of viral mechanisms that
inhibit type I interferon-dependent signaling and gene expres-
sion. Young et al. (2000) reported that type I interferon-
mediated promoter activation, ISGF3 formation, and Stat1 and
Stat2 levels were not decreased after 8–16 h of infection with
RSV strain A2 in 2fTGH human diploid fibroblast cells.
However, we have found that human fibroblasts and other
nonepithelial cells require longer durations of infection to
manifest RSV effects on type I interferon signaling (results not
shown). Thus, differences between our studies and other
reports may be due to differences in experimental systems
including cell culture conditions, viral strain, infection inocu-
lum, timing of infection relative to interferon treatment, or use
of airway epithelial cells (the natural host cell for this virus).
Our model system is designed to test conditions during initial
viral infection of human airway epithelial cells prior to
interferon generation.
There is growing evidence indicating that human RSV
nonstructural proteins function to subvert interferon-dependent
immunity. This is in light of the observation that RSV lacks
proteins with significant sequence homology to the C and V
accessory proteins that mediate interferon resistance in many
paramyxoviruses. RSV NS1 and NS2 proteins are deemed
‘‘accessory proteins’’ due to their initial unknown functions, the
ability of the virus to replicate when these genes are deleted,
and the historical difficulty involved in detection of these
proteins in virus replicating cell systems. However, replication
of recombinant human RSV that lack NS1 and/or NS2
expression is attenuated in systems that produce type I
interferon, including cultured cells, mice, and primates, but is
restored when grown in interferon-deficient Vero cells (Jin et
al., 2000, 2003; Teng and Collins, 1999; Teng et al., 2000;
Whitehead et al., 1999). Furthermore, the NS1 and NS2
proteins of bovine RSV have been shown to suppress the
induction of type I interferon and activation of the IFN-
mediated antiviral state, and attenuated growth of NS1- and
NS2-deleted bovine RSV is also restored in Vero cells (Bossert
and Conzelmann, 2002; Bossert et al., 2003; Schlender et al.,
2000; Valarcher et al., 2003). The mechanism for this effect
appears to be through suppression of the activation of IRF-3 by
bovine RSV NS1 and NS2 (Bossert et al., 2003). Bovine RSVNS1 and NS2 proteins share a 69% and 84% amino acid
identity with the respective proteins in human RSV subgroup A
(Pastey and Samal, 1995). Thus, it is not surprising that human
RSV inhibits type I interferon release through a similar effect of
NS1 and NS2 on IRF-3 (Spann et al., 2004; Spann et al., 2005).
RSV also appears to have the capacity to specifically bypass
the effects of type I interferon-induced MxA and other
undefined antiviral proteins (Atreya and Kulkarni, 1999).
Thus, RSV uses a common set of proteins to affect multiple
mechanisms that modulate interferon-dependent immunity,
highlighting the importance of bypassing this system in order
to allow efficient virus propagation.
The use of primary human airway epithelial cells (the
natural host cell in the airway) was emphasized in most of our
experiments. However, the use of RNA interference presented
a relatively novel approach to study the function of RSV NS
genes. For these experiments, altered viral gene expression was
required in the majority of cells in the sample in order to detect
effects on Stat2. A549 respiratory epithelial cells displayed
similar RSV effects on Stat2 expression, but provided better
transfection efficiency than hTBE cells (results not shown).
Specific inhibition of NS2 expression was accomplished with
RNA interference and suggested an important role for this viral
protein in modulation of type I interferon signaling. Although
other reports indicate successful inhibition of NS1 expression
using siRNA, the reasons for incomplete separation of NS1
siRNA effects from NS2 despite the use of multiple strategies
in our experiments are unclear (Zhang et al., 2005). Thus, to
more completely separate the effects of the two RSV
nonstructural proteins, subsequent experiments were performed
with recombinant virus deficient in NS gene expression.
Previous reports indicated that deletion of RSV NS1 or
NS2 impaired viral replication in airway epithelial cells in the
presence of endogenous (or exogenous) type I interferon, but
had less effect in Vero cells that do not release type I
interferon in response to virus infection (Lo et al., 2005;
Spann et al., 2004). This not only supported the possibility
that NS genes played a role in interferon resistance, but also
supported the possibility that the use of recombinant viruses
would allow separation of functional effects of the two viral
genes. For our experiments, Vero cells were used for initial
confirmation of inhibition of type I interferon-dependent gene
(MxA and PKR) expression during infections in which NS2
was expressed. Interestingly, subsequent studies with hTBE
cells under conditions of endogenous interferon release
indicated that MxA levels were higher after infection with
NS2-deleted RSV, indicating higher sensitivity to interferon-
or noninterferon-dependent induction. Indeed, this occurred
under conditions in which NS2-deleted RSV induces lower
levels of IFN-h release (Spann et al., 2004). In contrast, with
NS1-deleted RSV, the expression of MxA in hTBE cells was
lower despite comparable or increased levels of type I
interferon release compared to wild-type virus infection,
suggesting that the presence of NS2 in NS1-deleted RSV
still inhibits type I interferon-dependent signaling and
subsequent gene expression (Spann et al., 2004). Similar
augmentation of MxA expression was seen after A549 cell
M. Ramaswamy et al. / Virology 344 (2006) 328–339336infection with RSV in which NS2 gene expression was
silenced by RNA interference. A difference in results between
experiments using mutant RSV and RNA interference was
seen under conditions with loss of NS1 expression, and this is
likely due to nonspecific NS1 siRNA effects that decrease
NS2 expression and thereby allow functional type I interferon
signaling. Thus, it appears that both RSV nonstructural
proteins have complex and interacting effects on epithelial
cell antiviral defense, and may have effects on viral replication
independent of interferon release or signaling. When RSV
NS1 and NS2 are present together, they perform different and
complementary functions that provide greater viral resistance
to interferon-dependent antiviral systems.
We speculate that RSV evolution was driven to generate a
mechanism to decrease Stat2 levels and thereby inhibit
interferon signaling because airway levels of type I interferon
that are commonly induced by the virus could inhibit viral
replication (Garofalo et al., 1996; Jamaluddin et al., 2001).
Although RSV NS1 partially suppresses type I interferon
production in infected cells, interferon may also be released by
leukocytes and other cells during viral infection (Diaz et al.,
1999; Legg et al., 2003; Preston et al., 1995; Salkind et al.,
1991; Spann et al., 2004, 2005). Thus, RSV NS1 and NS2 are
likely both required for viral subversion of the antiviral effects
of type I interferon. A better understanding of viral mechan-
isms for altering interferon-dependent immune responses may
allow for the development of therapeutic strategies that block
this viral capacity during infection of airway epithelium.
Materials and methods
Cell isolation, culture, and stimulation
Human tracheobronchial epithelial cells were obtained
under a protocol approved by the University of Iowa
Institutional Review Board. Epithelial cells were isolated from
tracheal and bronchial mucosa by enzymatic dissociation and
cultured in a Laboratory of Carcinogenesis (LHC)-8e medium
on plates coated with collagen/albumin for study up to passage
10 as described previously (Aldallal et al., 2002; Look et al.,
1992). The A549 respiratory epithelial cell line (American
Type Culture Collection CCL-185, Manassas, VA) was
cultured in RPMI 1640 medium supplemented with 10% heat
inactivated (56 -C for 1 h) FBS, 2 mM l-glutamine, 100 U/ml
penicillin, 100 Ag/ml streptomycin, and 0.25 AM amphotericin
B as described previously (Frick et al., 2000). The Vero African
green monkey kidney cell line (American Type Culture
Collection CCL-81) was cultured in minimum essential
medium (Eagle) supplemented with 10% heat inactivated
FBS, 2 mM l-glutamine, 100 U/ml penicillin, 100 Ag/ml
streptomycin, 0.1 mM nonessential amino acids, and 1 mM
sodium pyruvate. Cells were treated with recombinant human
IFN-a2a (PBL Biomedical Laboratories, Piscataway, NJ) at a
concentration (1000 units/ml) and for a duration (0.25–24 h)
that result in maximal effects on type I interferon JAK-STAT
pathway component phosphorylation and gene expression.
Some cells were treated with recombinant human IFN-g (a giftfrom Genentech, San Francisco, CA) at a concentration (100
units/ml) and for a duration (0.5 h) that result in maximal
effects on Stat1 phosphorylation. In some experiments, cells
were treated with the cell-permeable nonspecific proteasome
inhibitor carbobenzoxy-l-leucyl-l-leucyl-l-leucinal (MG-132,
Calbiochem, San Diego, CA).
Viral preparation and infection
RSV with deletion of the NS1 or NS2 genes (gifts from H.
Jin, MedImmune, Gaithersburg, MD) (Jin et al., 2000) and
wild-type RSV strain A2 were purified from Vero cell lysates
by pelleting using centrifugation at 100,000  g for 45 min at 4
-C. RSV were incubated with epithelial cells for 6–24 h in
culture media at 37 -C in 5% CO2 at an MOI of 15, based on
plaque titration assay using Vero cells. Efficiency of epithelial
cell infection was determined using immunofluorescence
staining for RSV proteins as described previously (Ramas-
wamy et al., 2004). Recombinant vaccinia viruses expressing a
specific RSV protein or control h-galactosidase (gifts from G.
Wertz, University of Alabama at Birmingham) were prepared
as described previously (Ball et al., 1986; Cherrie et al., 1992;
Johnson et al., 1998; Wertz et al., 1987).
Primary antibodies
Rabbit polyclonal IgG 06-502 against total human Stat2,
rabbit polyclonal IgG 07-224 against phosphorylated human
Stat2, and rabbit polyclonal IgG 06-638 against total human
Tyk2 were from Upstate Biotechnology (Lake Placid, NY);
goat polyclonal IgG against human RSV proteins was from
Biodesign International (Saco, ME); rabbit polyclonal antise-
rum against RSV NS1 that faintly recognizes NS2 was from H.
Jin (MedImmune); mouse IgG2a mAb clone AC-74 against
human h-actin was from Sigma-Aldrich (St. Louis, MO);
chicken polyclonal IgY against human MxA was from BacLab
(Muttenz, Switzerland); rabbit polyclonal IgG 3072 against
human PKR, rabbit polyclonal IgG 9171 against phosphory-
lated human Stat1, rabbit polyclonal IgG 9172 against total
human Stat1, and rabbit polyclonal IgG 9321 against phos-
phorylated human Tyk2 were from Cell Signaling Technology
(Beverly, MA).
Immunoblot analysis
Cell protein levels were assessed by immunoblot analysis
using specific antibodies against human JAK-STAT pathway
components as described previously (Joseph and Look, 2001;
Look et al., 1998; Ramaswamy et al., 2004). Whole cell protein
extracts were prepared by lysis of cell monolayers in 50 mM
Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, a protease
inhibitor cocktail (Roche Bioscience, Palo Alto, CA), and a
phosphatase inhibitor panel (Calbiochem). Protein concentra-
tions were determined using a Coomassie brilliant blue G-250
binding assay (Bio-Rad Laboratories, Hercules, CA) and equal
amounts of cell protein were subjected to SDS-PAGE in 5–
18% polyacrylamide. Resolved proteins were electrophoreti-
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sham Biosciences, Piscataway, NJ), exposed to 5% nonfat milk
in Tris-buffered saline with 0.1% Tween-20 to block nonspe-
cific antigens, and then incubated with antibodies against a
specific cellular protein. Primary antibody binding was
detected using rabbit antichicken IgY (Sigma-Aldrich, St.
Louis, MO), goat antirabbit IgG (Santa Cruz Biotechnology,
Santa Cruz, CA), goat antimouse IgG (Boehringer Mannheim,
Indianapolis, IN), or donkey antigoat IgG (Santa Cruz)
conjugated to horseradish peroxidase and an enhanced chemi-
luminescence detection system (Amersham Biosciences).
Reprobing of membranes with a different primary antibody
was done after washing in Restorei buffer (Pierce, Rockford,
IL) for 15 min at 37 -C.
Cytotoxicity assays
Dead and live hTBE cell numbers were quantified by
detection of plasma membrane permeability to ethidium
homodimers in dead cells and intracellular esterase activity in
live cells using a commercial fluorescence-based viability and
cytotoxicity kit (Molecular Probes, Eugene, OR).
RNA interference
Sequence-specific 21 nucleotide double-stranded RNA
molecules that target RSV mRNA sequences were synthesized
(Dharmacon, Lafayette, CO) and transfected into A549 cells at
a concentration of 100 nM using Lipofectamine2000 (Invitro-
gen, Carlsbad, CA) as described previously (Bitko and Barik,
2001). The following dsRNA sequences with 3V-extensions
consisting of two 2V-deoxythymidines were used: (1) RSV NS1
gene forward 5V-GUGAUUCAACAAUGACCAATT-3V and
reverse 5V-UUGGUCAUUGUUGAAUCACTT-3V; (2) RSV
NS2 gene forward 5V-GACAUGAGACCGUUGUCACTT-3V
and reverse 5V-GUGACAACGGUCUCAUGUCTT-3V; and (3)
RSV P gene forward 5V-CGAUAAUAUAACUGCAAGATT-3V
and reverse 5V-UCUUGCAGUUAUAUUAUCGTT-3V. Se-
quence-specific 25–27 nucleotide double-stranded RNA mole-
cules that target RSV mRNA sequences were synthesized
(Integrated DNA Technologies, Coralville, IA) and transfected
into A549 cells at a concentration of 25 nM using Lipofecta-
mine2000 as described previously (Kim et al., 2004). The
following dsRNA sequences with the forward sequence
containing a 5V-phosphorylation and two 2V-deoxynucleotides
at the 3V-end and the reverse sequence containing a two
nucleotide 3V-overhang were used: RSV NS1 gene forward 5V-
GGCAGCAAUUCAUUGAGUAUGAUAA-3V and reverse 5V-
UUAUCAUACUCAAUGAAUUGCUGCCCA-3V. Scrambled
sequences were used as controls.
Real-time reverse transcription PCR mRNA analysis
Total cellular RNA was isolated using a commercial spin
column isolation kit (Stratagene, La Jolla, CA), and 0.5 Ag
reverse transcribed using a RT-PCR kit (Ambion, Austin, TX).
An aliquot of cDNAwas subjected to PCR using an iCycler iQFluorescence Thermocycler (Bio-Rad, Hercules, CA) with
SYBR Green I DNA dye (Molecular Probes, Eugene, OR),
and Platinum Taq DNA Polymerase (iQ SYBR Green Super-
mix kit, BioRad). PCR conditions included denaturation at 95
-C 3 min, then for 35 cycles of 94 -C 30 s, 60 -C 30 s, and 72
-C 30 s, followed by 5 min at 72 -C for elongation. The
following primers were used: (1) RSV NS1 gene forward 5V-
AGAGATGGGCAGCAATTCAT-3V and reverse 5V-CCAT-
TAGGTTGAGAGCAATGTG-3V; (2) RSV NS2 gene forward
5V-ATGGACACAACCCACAATGA-3V and reverse 5V-
TGCCAATGCATTCTAAGAACC-3V; (3) RSVMgene forward
5V-TCACGAAGGCTCCACATACA-3V and reverse 5V-
GCCTTGATTTCACAGGGTGT-3V; (4) MxA gene forward
5V-GAAGCCCTGCAGAGAGAGAA-3V and reverse 5V-AACT-
CGTGTCGGAGTCTGGT-3V; and (5) human hypoxanthine
phosphoribosyltransferase (HPRT) forward 5V-CCTCATG-
GACTGATTATGGAC-3 V and reverse 5 V-CAGATT-
CAACTTGCGCTCATC-3V. Fluorescence data were captured
during the 10 s dwell to ensure that primer dimers were not
contributing to the fluorescence signal, and specificity of the
amplification was confirmed using melting curve analysis. Data
were collected and recorded by iCycler iQ software (Bio-Rad)
and initially determined as a function of threshold cycle (Ct).
Levels of mRNA are expressed relative to control HPRT levels,
calculated as 2DCt.
Enzyme-linked immunoassay
IFN-h concentrations in cell culture media were determined
using a highly selective, commercial sandwich ELISA kit (PBL
Biomedical Laboratories, Piscataway, NJ).
Statistical analysis
Numerical data were analyzed for statistical significance
using a one-way ANOVA for a factorial experimental design.
The multicomparison significance level for the one-way
analysis of variance was 0.05. If significance was achieved
by one-way analysis, post-ANOVA comparison of means was
performed using Scheffe F tests (Zar, 1984).
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